Clear Point Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 13 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.90 M
- Revenue Growth 57.58%
- Profit Growth 106.78%
- Ebitda 62.45%
- Net Worth 27.30%
- Total Assets 8.76%
About Clear Point Pharma
Clear Point Pharma Private Limited (CPPPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 06 May 2011 and has a history of 13 years and nine months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.90 M.
Narendra Bamne, Ramesh Bamane, and Neha Bamne serve as directors at the Company.
Company Details
-
Location
Mumbai, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909MH2011PTC217148
-
Company No.
217148
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
06 May 2011
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Clear Point Pharma?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narendra Bamne
|
Director | 17-Mar-2023 | Current |
|
Ramesh Bamane
|
Additional Director | 01-Oct-2012 | Current |
|
Neha Bamne
|
Director | 13-Apr-2019 | Current |
Financial Performance of Clear Point Pharma.
Clear Point Pharma Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 57.58% increase. The company also saw a substantial improvement in profitability, with a 106.78% increase in profit. The company's net worth Soared by an impressive increase of 27.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Clear Point Pharma?
In 2022, Clear Point Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹5.90 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.45 Cr
- Hdfc Bank Limited : 0.14 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 14 Jul 2023 | Hdfc Bank Limited | ₹1.40 M | Open |
| 05 Mar 2014 | Others | ₹4.50 M | Open |
How Many Employees Work at Clear Point Pharma?
Unlock and access historical data on people associated with Clear Point Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Clear Point Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Clear Point Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
